NC-NOVAQUEST-CAPITAL
20.5.2021 12:32:11 CEST | Business Wire | Press release
Argenta Limited (“Argenta”), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management (“NovaQuest”) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005132/en/
The collaboration leverages NovaQuest’s capital and expertise, and Argenta’s knowledge and know-how in research and development activities that advance animal health.
“The capital investment from NovaQuest accelerates Argenta’s strategy of providing innovative solutions and Molecule to Market services through global partnerships. We are delighted by the collaboration with NovaQuest and we look forward to strengthening our partnership through additional programs in the future,” said Ben Russell, CEO of Argenta.
Argenta will conduct the R&D activities from its locations in the United States and New Zealand and will use proprietary drug delivery technologies to develop what are expected to be the next generation of veterinary pharmaceutical products. Argenta and NovaQuest will look for commercialization partners as the project progresses.
“This is an historic milestone for Argenta and instrumental in advancing our commitment to deliver innovation to the animal health industry. I am excited to leverage our product development expertise, IP and technology to accelerate some of the many options available,” commented Edward McGruder, Global head of Research, Development and Innovation at Argenta.
For NovaQuest, a premier biopharma and life sciences investment firm with extensive experience in human health product financing, this represents their first expansion into a collaboration of this nature within the animal health industry.
“We are excited to enter into this collaboration with Argenta, a trusted global leader in the animal health industry. With this investment we expand NovaQuest’s commitment to funding innovation in animal health across a wide range of companies and products,” said Jonathan Tunnicliffe, Chief Investment Officer of NovaQuest.
“NovaQuest’s commitment to bringing innovation to the animal health industry, combined with Argenta’s unparalleled end-to-end development capabilities and expertise make this a truly exciting collaboration,” said Brian Axe, Managing Director at NovaQuest .
Both companies are eager to start this product development journey to help accelerate innovation in the animal health industry.
Wyrick Robbins Yates & Ponton LLP acted as legal counsel to NovaQuest.
About NovaQuest
Founded by a team of accomplished industry professionals who began working together in 2000, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a Product Finance solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate higher than the industry average. Currently managing more than $2.2 billion in capital, NovaQuest is actively investing from the $1.2 billion Pharma Opportunities Fund V, evaluating global opportunities with financing needs that range from $30-100 million. Leveraging the core platform, NovaQuest is expanding its strategy to bring much needed capital to the animal health industry. NovaQuest is actively evaluating and investing in opportunities across animal segments and geographies. For more information, please visit www.novaquest.com
About Argenta
Argenta is the only combined global contract research organization (CRO) and contract development and manufacturing organization (CDMO) dedicated to animal health. Founded in 2006 in New Zealand, Argenta’s talented, diverse and committed employees work on a daily basis to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States and the United Kingdom, Argenta operates ‘from Molecule to Market’ in partnership with its customers to support their R&D, regulatory, clinical research and manufacturing needs along the veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 19:16:00 CEST | Press release
Canadian-led expansion will build the world’s largest and most capable C-130 airtanker fleet Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s g
Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets7.8.2026 18:16:00 CEST | Press release
Partnership combines Energy Vault's FEOC-compliant BESS, grid-forming PCS, and AI infrastructure control software with partner’s turnkey power generation, Caterpillar gensets and EPC capabilitiesReference architecture delivers firm grid-independent power, essential grid stabilization and load balancing to deliver modular, scalable, gigawatt-scale AI campuses with "always-on" availabilitySecond strategic framework agreement together advances Energy Vault's AI infrastructure strategy and establishes a repeatable “speed-to-power” deployment platformInitial 1.25 GW is backed by a hyperscaler customer contract for deployment in TexasEnergy Vault expects a revenue impact of ~$500 - $600 million in 2H 2026 and 2027, which will be discussed during the upcoming earnings call on August 11, 2026 Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault
SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 10:52:00 CEST | Press release
IRIS² expands SES's differentiated MEO architecture while supporting Europe's secure, sovereign multi-orbit connectivity ambitions SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously commun
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 07:10:00 CEST | Press release
2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SETotal business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment effec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom